Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C16H13ClN2O2.ClH |
| Molecular Weight | 337.201 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CN1C2=CC=C(Cl)C=C2C(=NC(O)C1=O)C3=CC=CC=C3
InChI
InChIKey=GPVUAFAZVYNKRQ-UHFFFAOYSA-N
InChI=1S/C16H13ClN2O2.ClH/c1-19-13-8-7-11(17)9-12(13)14(18-15(20)16(19)21)10-5-3-2-4-6-10;/h2-9,15,20H,1H3;1H
| Molecular Formula | C16H13ClN2O2 |
| Molecular Weight | 300.74 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: http://www.drugbank.ca/drugs/DB00231Curator's Comment: Description was created based on several sources, including
http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/018163s054lbl.pdf
Sources: http://www.drugbank.ca/drugs/DB00231
Curator's Comment: Description was created based on several sources, including
http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/018163s054lbl.pdf
Temazepam is a benzodiazepine used as a hypnotic agent in the management of insomnia. Temazepam produces CNS depression at limbic, thalamic, and hypothalamic levels of the CNS. Temazepam increases the affinity of the neurotransmitter gamma-aminobutyric acid (GABA) for GABA receptors by binding to benzodiazepine receptors. Results are sedation, hypnosis, skeletal muscle relaxation, anticonvulsant activity, and anxiolytic action. Benzodiazepines bind nonspecifically to benzodiazepine receptors, which affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABAA) receptors, this enhances the effects of GABA by increasing GABA affinity for the GABA receptor. Binding of the inhibitory neurotransmitter GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell. Temazepam is used for the short-term treatment of insomnia (generally 7-10 days).
CNS Activity
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1560 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2574013 |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
TEMAZEPAM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
964 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8181199 |
26 mg single, intravenous dose: 26 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
TEMAZEPAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
865 ng/mL |
30 mg 1 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
TEMAZEPAM plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
6.4 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8181199 |
26 mg single, intravenous dose: 26 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
TEMAZEPAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1800 ng × h/mL |
30 mg 1 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
TEMAZEPAM plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1.24 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2574013 |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
TEMAZEPAM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
10.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8181199 |
26 mg single, intravenous dose: 26 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
TEMAZEPAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
8.8 h |
30 mg 1 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
TEMAZEPAM plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8181199 |
26 mg single, intravenous dose: 26 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
TEMAZEPAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
4% |
30 mg 1 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
TEMAZEPAM plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
26 mg single, intravenous Dose: 26 mg Route: intravenous Route: single Dose: 26 mg Sources: |
healthy, 18 - 24 years Health Status: healthy Age Group: 18 - 24 years Sex: M+F Sources: |
|
40 mg single, oral |
unhealthy, 42 years (range: 22 - 59 years) Health Status: unhealthy Age Group: 42 years (range: 22 - 59 years) Sex: M+F Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Effect of low-dose temazepam on physiological variables and performance tests following a westerly flight across five time zones. | 2001 Apr |
|
| Direct LC analysis of five benzodiazepines in human urine and plasma using an ADS restricted access extraction column. | 2001 Dec |
|
| Culture of porcine hepatocytes: the dogma of exogenous matrix revisited. | 2001 Jul |
|
| Treatment of insomnia in hospitalized patients. | 2001 Nov |
|
| A combination of intrathecal morphine and remifentanil anesthesia for fast-track cardiac anesthesia and surgery. | 2002 Dec |
|
| Severe vein damage caused by Temezepam injecting. | 2002 Feb |
|
| Are changes in beliefs and attitudes about sleep related to sleep improvements in the treatment of insomnia? | 2002 Jul |
|
| Prediction of poly(ethylene) glycol-drug eutectic compositions using an index based on the van't Hoff equation. | 2002 Mar |
|
| Analytical developments in toxicological investigation of drug-facilitated sexual assault. | 2003 Aug |
|
| Errors in performance testing: a comparison of ethanol and temazepam. | 2003 Mar |
|
| Neurobehavioural performance effects of daytime melatonin and temazepam administration. | 2003 Sep |
|
| Toward evidence-based prescribing at end of life: a comparative review of temazepam and zolpidem for the treatment of insomnia. | 2003 Sep-Oct |
|
| Pharmacokinetics and drug interactions of the sedative hypnotics. | 2003 Winter |
|
| Quantitation of drug metabolites in the absence of pure metabolite standards by high-performance liquid chromatography coupled with a chemiluminescence nitrogen detector and mass spectrometer. | 2004 |
|
| Screening, library-assisted identification and validated quantification of 23 benzodiazepines, flumazenil, zaleplone, zolpidem and zopiclone in plasma by liquid chromatography/mass spectrometry with atmospheric pressure chemical ionization. | 2004 Aug |
|
| Zolpidem is not superior to temazepam with respect to rebound insomnia: a controlled study. | 2004 Aug |
|
| Monitoring of drugs and metabolites in whole blood by restricted-access solid-phase microextraction coupled to liquid chromatography-mass spectrometry. | 2004 Jan 30 |
|
| Sleep-inducing pharmaceuticals: a comparison of melatonin, zaleplon, zopiclone, and temazepam. | 2004 Jun |
|
| [Diphenhydramin-overdose: anticholinergic symptoms, EEG-findings in the course and drug treatment of a gerontopsychiatric patient]. | 2004 Nov |
|
| Effects of zolpidem and temazepam on driving ability. | 2004 Nov |
|
| Alcohol and other drug use in later life. | 2004 Oct |
|
| 'Hypnotic' prescription patterns in a large managed-care population. | 2004 Sep |
|
| The effects of restricting publicly subsidised temazepam capsules on benzodiazepine use among injecting drug users in Australia. | 2004 Sep 20 |
|
| Effects of co-medicated drugs on cyclophosphamide bioactivation in human liver microsomes. | 2005 Mar |
Patents
Sample Use Guides
While the recommended usual adult dose is 15 mg before retiring, 7.5 mg may be sufficient for some patients, and others may need 30 mg. In transient insomnia, a 7.5 mg dose may be sufficient to improve sleep latency. In elderly or debilitated patients, it is recommended that therapy be initiated with 7.5 mg until individual responses are determined.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 21:00:29 GMT 2025
by
admin
on
Mon Mar 31 21:00:29 GMT 2025
|
| Record UNII |
IA4EP07006
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
97598-16-8
Created by
admin on Mon Mar 31 21:00:29 GMT 2025 , Edited by admin on Mon Mar 31 21:00:29 GMT 2025
|
PRIMARY | |||
|
DBSALT002272
Created by
admin on Mon Mar 31 21:00:29 GMT 2025 , Edited by admin on Mon Mar 31 21:00:29 GMT 2025
|
PRIMARY | |||
|
70376607
Created by
admin on Mon Mar 31 21:00:29 GMT 2025 , Edited by admin on Mon Mar 31 21:00:29 GMT 2025
|
PRIMARY | |||
|
IA4EP07006
Created by
admin on Mon Mar 31 21:00:29 GMT 2025 , Edited by admin on Mon Mar 31 21:00:29 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
